Oh My Meds Expands Telehealth Services Nationwide For GLP-1 Weight Management And Diabetes Treatment

2025-07-02 03:06:16

(MENAFN- GetNews) FDA-Regulated Prescriptions and Physician-Guided Care Now Available Online in All 50 U.S. States.

Oh My Meds, a U.S.-based telehealth platform, has officially expanded its services to all 50 states, providing adults with access to physician-guided GLP-1 treatment plans for weight management and Type 2 diabetes care. Through a fully digital model, the company offers qualified patients medications such as Semaglutide and Tirzepatide delivered directly to their homes, typically within a few business days.

The announcement marks a significant milestone in the company's effort to make clinical support for metabolic health more accessible and convenient, particularly for those seeking alternatives to traditional in-office care models.

“We built Oh My Meds to give people a healthcare experience that is fast, trustworthy, and focused on delivering results,” said a company spokesperson.“Our goal is to simplify access to treatment by removing unnecessary delays and administrative barriers.”

Simple Process, Transparent Pricing

The Oh My Meds platform allows individuals to begin treatment online in just a few steps:

Complete a medical screening – Patients complete a brief health questionnaire and meet with a licensed U.S. doctor via telehealth.

Medication ships quickly – Once approved, prescriptions are filled by FDA-regulated 503A pharmacies and shipped in climate-controlled packaging.

Ongoing medical support – Patients receive continuous access to follow-up care through a dedicated support team available via a secure portal.

The service is offered at a flat price that includes the initial consultation, medication, shipping, and continued medical support. The company states that there are no subscription fees or unexpected charges, and all dosages are priced equally.

Clinically-Guided Treatment Model

Oh My Meds' treatment plans are overseen by licensed U.S. medical professionals. Medications are compounded in compliance with FDA standards at registered 503A pharmacies and undergo third-party laboratory testing for potency and purity. The platform's care team remains in contact with patients throughout the treatment journey, offering dosage adjustments and support based on clinical response.

“This approach supports individuals through a medically appropriate pathway using established protocols and consistent follow-up,” the spokesperson added.

Future Offerings

In addition to GLP-1 treatments, Oh My Meds plans to introduce a selection of peptide therapies in May 2025. These therapies will include options for energy, cognitive function, and muscle support, with additional formulations designed to complement metabolic health and reduce certain side effects.

To qualify for low cost GLP1 treatment, sign up at Oh My Meds at

About Oh My Meds

Headquartered in Windermere, Florida, Oh My Meds is a telehealth provider offering access to doctor-supervised treatments for weight management and Type 2 diabetes. The company operates a fully digital model, working exclusively with FDA-compliant U.S. pharmacies and licensed medical professionals. Oh My Meds is LegitScript-certified and focused on offering an efficient, transparent, and patient-centered approach to metabolic healthcare.

Disclaimer: This press release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Results may vary. All medical decisions should be made in consultation with a licensed healthcare provider. Oh My Meds does not claim to cure or prevent any disease. Medications referenced are compounded in accordance with applicable U.S. regulations and require a valid prescription from a licensed physician.

MENAFN02072025003238003268ID1109753575

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.